Kenvue Inc (KVUE)
Fair ValueFundamental
61
Price
$19.57
Market Cap
$36.57B
Part 1 · What the company is worth
Overview
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 19, 2026, shared with all users
The only competitor Kenvue lists in all three of its segments, with Vicks and Pepto-Bismol against Self Care, Olay against Neutrogena and Aveeno, and Crest and Always against Listerine and Stayfree.
The other large pure-play consumer health company, named by Kenvue in its own 10-K, competing for the same pharmacy and supermarket shelves in pain relief, oral care and cold and allergy remedies worldwide.
Named in Kenvue's 10-K as a Self Care rival: Nurofen, Mucinex and Strepsils go head to head with Tylenol, Motrin and Zyrtec in over-the-counter pain, cold and allergy products.
Named by Kenvue among its Skin Health and Beauty rivals: Nivea and Eucerin compete with Neutrogena and Aveeno for the same mass-market face and body care shopper.
Named in the same segment of Kenvue's 10-K: its mass brands, such as L'Oréal Paris, Garnier and CeraVe, fight for the same skincare and haircare shelf space as Neutrogena, Aveeno and OGX.
The largest maker of store-brand over-the-counter medicines in the United States, the private-label competition Kenvue's 10-K cites in every segment, selling the same active ingredients as Tylenol or Zyrtec at a lower price in the same aisle.
Balance Sheet & Liquidity
Revenue
$15.41B
Trailing 12 months (through 6/28/2026)
Net Income
$1.66B
Trailing 12 months (through 6/28/2026)
Free Cash Flow
$1.72B
Total Equity
$10.77B
Total Liabilities
$16.31B
Current Ratio
1.01
Interest Coverage
6.19
Debt/EBITDA
2.90
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$20.88
Current Price
$19.57
Margin of Safety
+6.3%
Fair Value Range
$13.58 - $28.19
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
22.76
ROE
13.7%
P/B Ratio
3.56
P/FCF
19.64
Gross Margin
58.2%
ROIC
10.0%
Profitability Radar
Value Creation (Economic Moat)
ROIC
10.0%
WACC
7.2%
ROIC − WACC
+2.7 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (17)
- ROIC 10.0%
- Gross margin 58.2%
- P/FCF 19.64
- Debt/equity ratio
- Operating margin 17.1%
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Debt/EBITDA
- Return on tangible assets
- ROE 15.6%
- Earnings surprise, average 9.5%
- Earnings quality (operating cash flow / net income) 1.40
- Share dilution 1.4%
- Net margin trend 10.8% vs 9.4%
- Piotroski F-Score 6/9
Failed (8)
- EPS shows upward trend
- EPS CAGR -10.98%
- Price CAGR -5.78%
- P/B ratio 3.56
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue growth 5Y 0.9%
Unavailable (2)
- Dividend payout –
- PEG ratio (needs P/E > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Share count is stable
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Kirk L. Perry | CEO & Director | 58 |
| Mr. Michael P. Wondrasch | Chief Technology & Data Officer | 56 |
| Mr. Matthew Orlando | General Counsel | 48 |
| Mr. Carlton Lawson | Group President of Europe, Middle East & Africa | 56 |
| Ms. Heather R. Howlett | Interim CFO & Chief Accounting Officer | 47 |
| Ms. Meredith Stevens | Chief Operations Officer | 62 |
| Dr. Caroline Tillett Ph.D. | Chief Scientific Officer | 53 |
| Ms. Sofya Tsinis | Head of Investor Relations | - |
| Mr. Jonathan Halvorson | Chief Digital & Marketing Officer | 42 |
| Mr. Anil Agarwal | Head of Total Rewards | - |
Audit Risk
4
Board Risk
3
Compensation Risk
6
Shareholder Rights Risk
7
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-20
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-06
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-10-13
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much KVUE moves, measured on its daily prices.
More volatile than 15% of the tracked stocks (90-day volatility).
- Volatility 30d
- 22.7%
- Volatility 90d
- 23.1%
- Beta vs S&P 500 (1y)
- 0.05Correlation 0.02
- Max drawdown (12m)
- -13.3%
- ATR (14d, % of price)
- 1.92%
Earnings reactions
How KVUE moved around its past quarterly results.
Next earnings release
Oct 30, 2026 · In 6 days · Before the open
EPS estimate: 0.29Revenue estimate: $3.9B
What usually happens
- Over the last 12 releases the stock moved a median of 4.3% the next day, up or down.
- Next-day moves: up 8, down 4 (out of 12).
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | During the session | 0.33 | 0.31 | -4.8% | -0.7% | -2.5% | -3.5% |
| May 7, 2026 | During the session | 0.27 | 0.32 | +19.6% | -1.0% | +0.2% | -2.8% |
| Feb 17, 2026 | After the close | 0.23 | 0.27 | +19.7% | +0.7% | +2.6% | +3.3% |
| Nov 3, 2025 | During the session | 0.27 | 0.28 | +3.5% | +18.8% | +12.3% | +17.5% |
| Aug 7, 2025 | During the session | n/a | n/a | n/a | -0.3% | +1.5% | +1.3% |
| May 8, 2025 | During the session | n/a | n/a | n/a | +6.0% | +4.1% | +0.4% |
| Feb 6, 2025 | During the session | n/a | n/a | n/a | -1.0% | -4.5% | +1.1% |
| Nov 7, 2024 | During the session | n/a | n/a | n/a | -1.5% | +2.1% | +2.8% |
| Aug 6, 2024 | During the session | n/a | n/a | n/a | +10.8% | +14.7% | +15.9% |
| May 7, 2024 | During the session | n/a | n/a | n/a | +1.9% | +5.2% | +6.7% |
| Feb 8, 2024 | During the session | n/a | n/a | n/a | -3.3% | -5.8% | -7.0% |
| Oct 26, 2023 | During the session | n/a | n/a | n/a | -4.5% | -5.3% | -4.3% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on KVUE and what the price did next.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for KVUE.
- 5d agoNEUTRALKimberly-Clark Raising $4.9 Billion for Tylenol Maker Takeover
Kimberly-Clark Corp. is preparing to raise $4.9 billion through an investment-grade bond issuance. This significant debt financing is earmarked to facilitate its pending acquisition of Kenvue Inc., the company behind the well-known Tylenol brand. While the acquisition itself may signal strategic expansion for Kimberly-Clark, the bond sale is primarily a financing event. For investors in Kenvue, this confirms the acquisition is progressing, but the immediate market impact is neutral as the deal is not yet closed and the financing method does not inherently alter Kenvue's intrinsic value.
- 11d agoNEUTRALKimberly-Clark, la Commissione UE approva l'acquisizione di Kenvue ma con condizioni
The European Commission has approved Kimberly-Clark's acquisition of Kenvue, but with conditions. This conditional approval means the deal can proceed, but requires adherence to specific commitments made by the companies to address potential antitrust concerns. While the green light is a significant step, the conditions could impact the integration process or future operational strategies. Investors will be monitoring the fulfillment of these commitments and their long-term implications for Kenvue's market position and Kimberly-Clark's strategic objectives.